Core Insights - Innovent Biologics showcased pre-clinical study results for IBI3011 and IBI3034 at the ACR Annual Meeting 2025, highlighting their potential in treating inflammatory and autoimmune diseases [1][2][5]. Group 1: IBI3011 - IBI3011 is a humanized monoclonal antibody that inhibits IL1, IL33, and IL36, effectively alleviating conditions like gout and arthritis in animal models [2][3]. - The drug demonstrates favorable pharmacokinetic properties and safety in monkeys, with a high concentration formulation developed for subcutaneous administration [3][4]. - IBI3011 has received IND approval from China's National Medical Products Administration for acute gouty arthritis, positioning it as a best-in-class therapy with improved response depth and convenience compared to existing treatments [4][7]. Group 2: IBI3034 - IBI3034 is a TACI/BCMA chimeric fusion protein that modulates B lymphocytes and serum immunoglobulin, showing promise for treating B cell-related autoimmune diseases [5][6]. - The drug features half-life extension technology, allowing for a longer dosing interval compared to current therapies, and is well tolerated in monkeys at a dosage of 200 mg/kg [5][6]. - Ongoing IND-enabling studies for IBI3034 aim to further establish its efficacy and safety profile in various autoimmune conditions [6][7]. Group 3: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for oncology, autoimmune, cardiovascular, and metabolic diseases [8][9]. - The company has launched 16 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline and commitment to addressing unmet medical needs [9].